Exscientia (NASDAQ:EXAI) Coverage Initiated at TD Cowen

TD Cowen began coverage on shares of Exscientia (NASDAQ:EXAI) in a research report released on Tuesday morning, Marketbeat.com reports. The brokerage issued a buy rating on the stock.

Separately, Morgan Stanley restated an equal weight rating and set a $7.00 price objective on shares of Exscientia in a research note on Monday, April 22nd. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Exscientia currently has a consensus rating of Moderate Buy and a consensus price target of $9.75.

Exscientia Stock Performance

EXAI opened at $5.69 on Tuesday. Exscientia has a 12-month low of $3.86 and a 12-month high of $9.12. The stock has a market cap of $687.85 million, a price-to-earnings ratio of -4.34 and a beta of 0.84. The business has a 50 day moving average of $5.19 and a 200-day moving average of $5.61. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.05.

Exscientia (NASDAQ:EXAI) last announced its earnings results on Tuesday, May 21st. The company reported ($0.21) earnings per share for the quarter. The firm had revenue of $6.70 million for the quarter. Exscientia had a negative return on equity of 34.59% and a negative net margin of 666.80%. On average, equities research analysts expect that Exscientia will post -1.07 earnings per share for the current year.

Hedge Funds Weigh In On Exscientia

Several hedge funds and other institutional investors have recently modified their holdings of EXAI. Banque Pictet & Cie SA bought a new position in shares of Exscientia in the 3rd quarter valued at $1,040,000. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Exscientia during the 4th quarter valued at $207,000. New Republic Capital LLC acquired a new stake in shares of Exscientia during the 4th quarter valued at $128,000. Jump Financial LLC boosted its holdings in shares of Exscientia by 47.7% during the 4th quarter. Jump Financial LLC now owns 53,755 shares of the company’s stock valued at $345,000 after acquiring an additional 17,355 shares in the last quarter. Finally, Colonial River Wealth Management LLC acquired a new position in Exscientia during the 4th quarter worth about $86,000. Institutional investors own 41.58% of the company’s stock.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.